# PRIORITY 1: DEFINITIONS
## INITIATIVE 1B: KEY PERFORMANCE INDICATORS

### Deliverable

- Establish clear DCT Benchmarks that highlight the productivity and impact of DCTs following the standard language from the Definitions Glossary.

**1B**

## AT A GLANCE

### High Level Description

- Standard set of KPIs to reference
  - Qualitative
    - Sentiment (which drives the quantitative return)
  - Quantitative
    - Decrease timeline for setup and database lock, for example

### Expected Timeline

- Mid-Term
- Approx. Start: 7-July-2021
- Duration: 180 Days

### External Spends

- None

### Database Requirements

- None

## KEY STAKEHOLDERS

### Industry Experts

- Investigators, internal leadership teams, Are there any companies willing to share their KPIs?

### Organizations

- Regulatory agencies

### Other Influencers

- Metrics Champion consortium (MCC – purchased by WCG)

## VALUE TO ACHIEVE

- Identification of best practices, challenges and the opportunity for improvement
- Faster enrollment, better patient engagement, improved patient experience
- Information from KPIs will help with change
- Speed to market would increase
- Enhanced patient diversity
- Value & Quality & Compliance
- Re-define the Benchmark we're evaluating against

## CHALLENGES TO ADDRESS

- Agreement on priorities - what matters most?
- What is the mark that we are making on the drug development industry?
- Re-educating Pharma & Biotech companies – new way of working / new ideas

## ACTIONS REQUIRED

- Derive KPIs from common language (the glossary)
- Define the value to the patient, provider, sponsor
- Comparison between traditional and DCT to satisfy challenges to the change

## POTENTIAL BARRIERS TO SUCCESS

- Prioritization and tracking